Joshua Richter, MD, discusses the available combination therapies for patients with early relapsed/refractory multiple myeloma using anti-CD38 monoclonal antibodies.
Joshua Richter, MD, associate professor of medicine, division of hematology and oncology, at the Tisch Cancer Institute, Icahn School of Medicine, and the director of multiple myeloma at the Blavatnik Family-Chelsea Medical Center at Mount Sinai, discusses the available combination therapies for patients with relapsed multiple myeloma.
Defining the different groups of early and late relapse, Richter highlights that therapy would be different for each. In the early relapse setting, the use of an anti-CD38 monoclonal antibody in combination with carfilzomib [Kyprolis] remains the best option. The current anti-CD38 therapies available to combine with carfilzomib are daratumumab [Darzalex] and isatuximab [Sarclisa].
Data supporting these combinations come from the phase 3 CANDOR study (NCT03158688) that showed that patients with relapsed/refractory multiple myeloma maintained their median progression-free survival (PFS) of 28.6 months (95% CI, 22.7–not estimable) compared with patients on carfilzomib alone (HR, 0.59; 95% CI, 0.45-0.78; P < .0001). In the phase 3 IKEMA study (NCT03275285), the addition of the anti-CD38 therapy isatuximab significantly improved PFS for these patients compared with carfilzomib and dexamethasone alone (HR, 0.53; 99% CI, 0.32-0.89; P = .0007). Looking at later-line relapses, Richter highlighted the continuing use of chimeric antigen receptor (CAR) T-cell therapy and novel bispecific antibodies.
Transcription:
0:07 | In general, when we talk about [patients with] relapsed myeloma, we talk about early relapses and late relapses. Early relapse is 1 to 3 prior lines of therapy and late relapses are 4 or more prior lines [of therapy]. And one of the areas that has really dominated the field of early relapse is CD38-based therapy, so daratumumab- and isatuximab-based combinations.
0:30 | Although we can combine these with a variety of therapies, we recognize that CD38 therapy plus Kyprolis has given us some of the most impressive data in the early relapse [setting], specifically with either daratumumab and Kyprolis or isatuximab and Kyprolis. For later line relapses, we're really looking towards the T-cell redirection therapies, like CAR T-cell therapy and bispecific antibodies.
Patient Preference Plays Limited Role in Selection of Therapy for Melanoma
May 17th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.
Read More
Discussing Non-Clinical Barriers to NGS Testing for NSCLC
May 15th 2024During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients with certain mutations of their non–small cell lung cancer in the first article of a 2-part series.
Read More
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Experience and Sequencing Guide Third-Line DLBCL Therapy Selection
May 13th 2024During a Case-Based Roundtable® event, Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma with event participants in the first article of a 2-part series.
Read More
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More